- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Imaging device stocks lagged in 1997
Shares of medical imaging device companies lagged behind almost all other healthcare sectors in 1997, according to a year-end review of the performance of healthcare stocks conducted by WDI Healthcare Markets Group of Hilton Head, SC. WDI's imaging
Shares of medical imaging device companies lagged behind almost all other healthcare sectors in 1997, according to a year-end review of the performance of healthcare stocks conducted by WDI Healthcare Markets Group of Hilton Head, SC. WDI's imaging devices segment fell 9% for the year, compared with an overall rise of 10% for healthcare stocks in general. Only two healthcare sectors, managed care and diagnostics, turned in worse performances.
The few stellar performers in WDI's imaging devices index included ATL Ultrasound, which rose 48%, and OEC Medical Systems, which climbed 33%. Trex Medical rose 7% and Norland Medical Systems climbed 11%. The index covers 25 public companies, including Acuson, Hologic, Lunar, ADAC Laboratories, and Fischer Imaging.
For most of these firms, it was tough sailing on the stock market, even though the medical imaging market posted a rebound in 1997. Part of the reason for the lower performance is that Wall Street has little patience for companies that turn in financial results even slightly shy of analysts' expectations, according to John Cumming, CEO of WDI.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
